Publications by authors named "C Duranton"

Claim this Profile
R
REACT-PXE: a consensus on diagnosis and future research concerning pseudoxanthoma elasticum (PXE).
L Martin, W Spiering, K Aelbrecht, T Aranyi, C Duranton

Ann Dermatol Venereol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting seryl-tRNA synthetase to unlock ischemic resilience in stroke - Insights from a proof-of-concept study.
Miled Bourourou, Nicolas Melis, Marc Cougnon, Gilbert Laffet, Christophe Duranton

J Cereb Blood Flow Metab· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of eIF5A hypusination enhances antioxidant defense to prevent kidney Ischemia/Reperfusion injury.
Marc Cougnon, Sébastien Giraud, Maria Materozzi, Elisa Allart, Isabelle Rubera, Christophe Duranton

Redox Biol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: The PROPHECI trial: a phase II, double-blind, placebo-controlled, randomized clinical trial for the treatment of pseudoxanthoma elasticum with oral pyrophosphate.
Laetitia Clotaire, Isabelle Rubera, Christophe Duranton, Jocelyn Gal, Emmanuel Chamorey

Trials· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PROPHECI trial: a phase II, double-blind, placebo-controlled, randomized clinical trial for the treatment of pseudoxanthoma elasticum with oral pyrophosphate.
Laetitia Clotaire, Isabelle Rubera, Christophe Duranton, Jocelyn Gal, Emmanuel Chamorey

Trials· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis